Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
AssigneeGenentech, Inc.
InventorsAlexander MUNK, Helene M. GYLLING, Jesse Eric HANSON, Lukasz J. KIELPINSKI
Life of this patent
Estimating the term…
Abstract
The present invention relates to complement component 1s (C1S) inhibitors for use in treatment of neurological diseases. The invention in particular relates to the use of C1S inhibitors for down-regulation of C1S expression. The invention also relates to nucleic acid molecules, which are complementary to C1S and capable of reducing the level of an C1S mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of neurological diseases.
Claims34
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A nucleic acid molecule of 12 to 30 nucleotides in length comprising a contiguous nucleotides sequence of at least 12 nucleotides which is at least 95% complementary to a mammalian C1R target sequence, wherein the nucleic acid molecule is capable of inhibiting the expression of a C1R mRNA.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.